D[LEU4,LYS8]-VP

D[LEU4,LYS8]-VP;

D[LEU4,LYS8]-VP 是血管加压素 V1b 受体的选择性激动剂,对大鼠,人类和小鼠 V1b 受体的 Ki 值分别为 0.16 nM,0.52 nM 和 1.38 nM。D[LEU4,LYS8]-VP 具有较弱的抗利尿剂、升压药和体外催产素活性。

D[LEU4,LYS8]-VPamp;;

D[LEU4,LYS8]-VP Chemical Structure

CAS No. : 42061-33-6

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

D[LEU4,LYS8]-VP 的其他形式现货产品:

D[LEU4,LYS8]-VP TFA

生物活性

D[LEU4,LYS8]-VP is a selective agonist of vasopressin V1b receptor, with the Kis of 0.16 nM, 0.52 nM, and 0.1.38 nM for rat, human and mouse V1b receptor, respectively. D[LEU4,LYS8]-VP has weak antidiuretic, vasopressor, and in vitro oxytocic activities[1][2].

IC50 Target

vasopressin V1b receptor[1]

分子量

1026.23

Formula

C47H67N11O11S2

CAS 号

42061-33-6

Sequence

{Mpa}-Tyr-Phe-Leu-Asn-Cys-Pro-Lys-Gly (Disulfide bridge:Mpa1-Cys6)

Sequence Shortening

{Mpa}-YFLNCPKG-NH2 (Disulfide bridge:Mpa1-Cys6)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
  • [1]. Ana P, et, al. Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors. Endocrinology. 2007 Sep; 148(9): 4136-46.

    [2]. Ana P, et, al. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8. J Med Chem. 2007 Feb 22; 50(4): 835-47.

Etoposide(Synonyms: 依托泊苷; VP-16; VP-16-213)

天然产物 天然产物苯丙素类 Phenylpropanoids

Etoposide (Synonyms: 依托泊苷; VP-16; VP-16-213) 纯度: 99.86%

Etoposide (VP-16; VP-16-213) 是一种常用的抗肿瘤化疗剂。Etoposide 抑制拓扑异构酶 II (topoisomerase-II),从而抑制 DNA 复制。Etoposide 诱导细胞周期停滞,凋亡 (apoptosis) 和自噬 (autophagy)。

Etoposide(Synonyms: 依托泊苷; VP-16;  VP-16-213)

Etoposide Chemical Structure

CAS No. : 33419-42-0

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥567 In-stock
100 mg ¥515 In-stock
200 mg ¥880 In-stock
500 mg ¥2000 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Etoposide 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Anti-Infection Compound Library
  • Apoptosis Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • Natural Product Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Glycoside Compound Library
  • Antibacterial Compound Library
  • NMPA-Approved Drug Library
  • Phenols Library
  • Orally Active Compound Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved & Pharmacopeial Drug Library
  • Antibiotics Library
  • Anti-Lung Cancer Compound Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Anti-Blood Cancer Compound Library
  • Mitochondria-Targeted Compound Library
  • Tumorigenesis Related Compound Library
  • Rare Diseases Drug Library
  • Children’s Drug Library

生物活性

Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy[1].

IC50 & Target[1]

Topoisomerase II

 

体外研究
(In Vitro)

Etoposide is capable of causing cytotoxicity on pancreatic β-cells by inducing apoptosis through the JNK/ERK-mediated GSK-3 downstream-triggered mitochondria-dependent signaling pathway in RIN-m5F cells[1].
Etoposide and Anti-Human VEGF significantly abolish P1 sphere-forming ability, an effect associated with apoptosis of this subset of cells[2].
Etoposide phosphate (0-1μM; 72 hours) inhibits HCT116 FBXW+/+, FBXW-/- and p53-/- as a dose-dependent manner, exhibits IC50s of 0.945 μM; 0.375 μM; and 1.437 μM, respectively[5].
Etoposide (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7-/- cells[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[5]

Cell Line: HCT116 FBXW+/+, FBXW-/- and p53-/- cells
Concentration: 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM
Incubation Time: 72 hours
Result: Inhibits HCT116 FBXW+/+p>, FBXW-/- and p53-/- cell growth as a concentration manner.

Western Blot Analysis[5]

Cell Line: HCT116 FBXW7+/+ or FBXW7-/- cells
Concentration: 25 μM
Incubation Time: 6 hours
Result: Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7.

体内研究
(In Vivo)

Etoposide (50 μM) and Anti-Human VEGF-treated hypoxic cells injected intravenously into immunodeficient mice reveals a reduced capacity to induce lung colonies, which also appear with a longer latency period[2]. Etoposide (10 mg/kg/day, i.v.) with NSC 109724 and NSC 241240, reduces the tumor volume in the hepatoblastoma cell injected NMRI nude mice[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

588.56

Formula

C29H32O13

CAS 号

33419-42-0

中文名称

依托泊苷;臼乙叉苷;足叶乙甙

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

DMSO : ≥ 39 mg/mL (66.26 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.6991 mL 8.4953 mL 16.9906 mL
5 mM 0.3398 mL 1.6991 mL 3.3981 mL
10 mM 0.1699 mL 0.8495 mL 1.6991 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.25 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.25 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

  • 3.

    请依序添加每种溶剂: 5% DMSO    40% PEG300    5% Tween-80    50% saline

    Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

  • 4.

    请依序添加每种溶剂: 5% DMSO    95% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

  • 5.

    请依序添加每种溶剂: 1% DMSO    99% saline

    Solubility: ≥ 0.5 mg/mL (0.85 mM); Clear solution

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Lee KI, et al. Etoposide induces pancreatic β-cells cytotoxicity via the JNK/ERK/GSK-3 signaling-mediated mitochondria-dependent apoptosis pathway. Toxicol In Vitro. 2016 Jul 26. pii: S0887-2333(16)30147-3.

    [2]. Calvani M, det al. Etoposide-Anti-Human VEGF a new strategy against human melanoma cells expressing stem-like traits. Oncotarget. 2016 Jun 9. doi: 10.18632/oncotarget.9939.

    [3]. Fuchs, J., et al. Comparative activity of NSC 119875, NSC 109724, NSC 123127, NSC 241240, and etoposide in heterotransplanted hepatoblastoma. Cancer, 1998. 83(11): p. 2400-7.

    [4]. Hande KR, et al. The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example. Oncologist. 1996;1(4):234-239.

    [5]. Cui D, et al. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.Cell Rep. 2020 Jan 14;30(2):497-509.e4.

Mosloflavone

天然产物 黄酮类 Flavonoids

Mosloflavone 

Mosloflavone 从 Scutellaria baicalensis Georgi 中分离出的类黄酮,具有抗 EV71 活性。Mosloflavone 在病毒感染的初始阶段抑制 VP2 病毒复制和蛋白质表达,并抑制病毒 VP2 衣壳蛋白合成。 Mosloflavone 是有前途的杀菌剂,可抑制铜绿假单胞菌的毒力和生物膜形成。

Mosloflavone

Mosloflavone Chemical Structure

CAS No. : 740-33-0

规格 价格 是否有货
5 mg ¥4030 询问价格 & 货期
10 mg ¥6860 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Mosloflavone is a flavonoid isolated from Scutellaria baicalensis Georgi with  anti-EV71 activity. Mosloflavone  inhibits VP2 virus replication and protein expression during the initial stage of virus infection and inhibits viral VP2 capsid protein synthesis. Mosloflavone is a promising biocide and inhibits P. aeruginosa virulence and biofilm formation.

IC50 & Target

IC50: EV71; bacterial[1][2]

体外研究
(In Vitro)

Mosloflavone shows promising anti-inflammatory activity via inhibition of TNF-α and IL-1β with IC50 values of 16.4 uM and 6.4 uM, respectively; inhibits TNF-α, IL-1β and iNOS levels in the supernatant of mouse macrophage cell line J774A as a dose-dependent manner, it also can be used as a starting point to discover lead structures for treatment of inflammatory and immunomodulatory diseases[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

298.29

Formula

C17H14O5

CAS 号

740-33-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. 2.Choi HJ, et al. Inhibitory Effects of Norwogonin, Oroxylin A, and Mosloflavone on Enterovirus 71.Biomol Ther (Seoul). 2016 Sep 1;24(5):552-8.

    [2]. 2.Hnamte S, et al. Mosloflavone attenuates the quorum sensing controlled virulence phenotypes and biofilm formation in Pseudomonas aeruginosa PAO1: In vitro, in vivo and in silico approach.Microb Pathog. 2019 Jun;131:128-134.

    [3]. 4.Singh B, et al. Anti-inflammatory and immunomodulatory flavones from Actinocarya tibetica Benth.Nat Prod Res. 2013;27(23):2227-30.

D[LEU4,LYS8]-VP TFA

D[LEU4,LYS8]-VP TFA; 纯度: 98.16%

D[LEU4,LYS8]-VP TFA 是血管加压素 V1b 受体的选择性激动剂,对大鼠,人类和小鼠 V1b 受体的 Ki 值分别为 0.16 nM,0.52 nM 和 1.38 nM。D[LEU4,LYS8]-VP TFA 具有较弱的抗利尿剂、升压药和体外催产素活性。

D[LEU4,LYS8]-VP TFAamp;;

D[LEU4,LYS8]-VP TFA Chemical Structure

规格 价格 是否有货 数量
5 mg ¥800 In-stock
10 mg ¥1300 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

D[LEU4,LYS8]-VP TFA 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Macrocyclic Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Peptide Library

生物活性

D[LEU4,LYS8]-VP TFA is a selective agonist of vasopressin V1b receptor, with the Kis of 0.16 nM, 0.52 nM, and 0.1.38 nM for rat, human and mouse V1b receptor, respectively. D[LEU4,LYS8]-VP TFA has weak antidiuretic, vasopressor, and in vitro oxytocic activities[1][2].

IC50 Target

vasopressin V1b receptor[1]

分子量

1140.25

Formula

C49H68F3N11O13S2

Sequence

{Mpa}-Tyr-Phe-Leu-Asn-Cys-Pro-Lys-Gly (Disulfide bridge:Mpa1-Cys6)

Sequence Shortening

{Mpa}-YFLNCPKG-NH2 (Disulfide bridge:Mpa1-Cys6)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献
  • [1]. Ana P, et, al. Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors. Endocrinology. 2007 Sep; 148(9): 4136-46.

    [2]. Ana P, et, al. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8. J Med Chem. 2007 Feb 22; 50(4): 835-47.